A surprising drug combo that could shift the Alzheimer’s conversation
Industry Buzz
What really mattered was behavior. If cognition is not improved, then the treatment doesn’t matter. And that’s where the combination clearly worked better than THC alone.
—Chu Chen, PhD
A small but intriguing preclinical study is drawing attention to the possibility that a compound familiar to many clinicians—THC, the principal psychoactive ingredient in marijuana —might play a role in preventing Alzheimer’s-like cognitive decline, but only when paired with a common anti-inflammatory drug. []
Researchers from the University of Texas at San Antonio Health Science Center (UT Health San Antonio) recently published an article in Aging and Disease showing that, in a mouse model of Alzheimer’s, low-dose THC and celecoxib (a COX-2 inhibitor) together produced measurable improvements in memory and reduced key markers of neurodegeneration. []
What did the study do?
In the experiment, mice genetically predisposed to develop Alzheimer’s-like pathology received daily doses of low-dose THC extract and celecoxib (administered 30 minutes before THC) for 30 days. []
While both agents have known anti-inflammatory effects on the nervous system, neither appeared sufficient on its own in this model.
THC alone reduced amyloid and tau pathology but increased inflammatory markers that could counteract the benefits.
The combination, however, improved cognition, reduced inflammation, and decreased Alzheimer’s-related brain pathology without the pro-inflammatory signal seen with THC alone.
"What really mattered was behavior. If cognition is not improved, then the treatment doesn’t matter. And that’s where the combination clearly worked better than THC alone," lead study author Chu Chen, PhD, professor in the Department of Cellular and Integrative Physiology at UT Health San Antonio, said in a news release. []
Why this matters
Several aspects of this research are worth underscoring for clinicians:
Both THC and celecoxib are already approved by the FDA, offering a potential fast track to early clinical trials if safety and efficacy can be demonstrated in humans.
The strategy highlights targeting neuroinflammation—a growing area of interest in Alzheimer’s pathogenesis.
Neuroprotective benefits without worsening inflammation, seen here with celecoxib neutralizing THC’s pro-inflammatory effect, suggest that synergistic treatment may be more effective than single agents.
That said, this is preclinical work: The study was conducted in mice before significant memory deficits developed, and human translatability is unknown at this stage.
Clinical context and cautions
For patients reading this news, it’s important that physicians aid in balancing excitement with caution.
Although cannabinoids, including THC and other constituents like CBD, are being explored in neurodegenerative conditions, human evidence remains limited and mixed, often focusing on symptom management such as agitation or sleep rather than on disease modification. []
Off-label or recreational cannabis use carries risks, including potential cognitive issues and associations with adverse outcomes in older adults. []
Related: An unpleasant syndrome surfaces as cannabis use growsCOX-2 inhibitors like celecoxib have their own cardiovascular and gastrointestinal risk profiles that must be weighed carefully in older patients, especially when considering long-term use. []
Related: Alzheimer’s starts in your 30s, says doc—here are 3 early blood markers that matter